In the version of this article initially published, it was stated that Denosumab had gained approval for use in osteoporosis treatment, when in fact it had only been recommended for approval. Additionally, the approval of its preventive use was recommended against until further data are available. The text should read “Several clinical trials tested this antibody, which counteracts bone loss. Although a US Food and Drug Administration committee recommended its approval for osteoporosis treatment, it recommended against approval of its preventive use—and its use to treat bone loss in certain cancer cases—until more data are available.” The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nm1209-1353a
Rights and permissions
About this article
Cite this article
Aranda, V. Erratum: Drugs in the headlines. Nat Med 16, 129 (2010). https://doi.org/10.1038/nm0110-129d
Issue Date:
DOI: https://doi.org/10.1038/nm0110-129d